Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib vs gemcitabine + cisplatin in FGFR2-rearranged cholangiocarcinoma
CTR20210272Phase 3Terminated
- Sponsor
- QED Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of infigratinib in intrahepatic cholangiocarcinoma (ICC), sponsored by QED Therapeutics. Started Feb 2021; status: terminated.
02
Drugs
infigratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20210272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210272.